Jongkundang has established a research and development subsidiary, Neurateon, to expand its R&D platform business. The company plans to provide R&D services to domestic and international pharmaceutical and biotech firms, covering areas from new drug research to technology transfer.
On July 8, Jongkundang held a founding ceremony for Neurateon at the Hyojong Research Institute in Dongbaek, Yongin. The event was attended by Choi Hee-nam, CEO of Jongkundang Holdings, along with Won Dong-han, CEO of Neurateon, and over 100 employees.
Neurateon will leverage the R&D capabilities and technologies accumulated at Jongkundang's Hyojong Research Institute to conduct the entire R&D process, including the development of new drug formulations, improved drugs, generics, and over-the-counter (OTC) products, as well as analytical research, formulation research, and drug delivery system (DDS) research.
The company aims to broaden its customer base among domestic and international pharmaceutical and biotech firms by expanding its own product development and technology transfer, positioning itself as a technology-driven R&D platform company.
The name Neurateon combines 'New Era' and 'Technology Innovation,' symbolizing the company's commitment to ushering in a new era in the pharmaceutical industry based on technological competitiveness.
During the ceremony, Neurateon presented its vision as a 'R&D platform company opening a new era through technological innovation' and outlined its mission to contribute to human health with differentiated technologies and innovative new products. Its core values include Technology, Collaboration, and Innovation.
Won Dong-han, a former executive at Jongkundang's research institute, has been appointed as the CEO of the newly established Neurateon. He holds a Ph.D. in pharmacy from Pusan National University and has 23 years of experience in technology research within the pharmaceutical and biotech sectors.
Won stated, 'Neurateon is a technology-based R&D platform company that provides the best services to our customers and partners based on excellent research personnel and expertise. We will differentiate through technology and expand through collaboration to open a new era in the future pharmaceutical industry.'
Since establishing the first central research institute in the domestic pharmaceutical industry in 1972, Jongkundang has continued to invest in raw material and finished product R&D and the training of research personnel.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.